Cervomed Inc. operates as a clinical stage biotechnology company. The Company develops and commercializes drug treatments for dementia with lewy bodies, alzheimer's disease, and other central nervous system disorders. CervoMed serves patients in the United States.

Current Report (Form 8-K | Period ending 2024-08-12)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CervoMed (CRVO US)

Current Report (Form 8-K | Period ending 2024-08-12)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

424B3 | Prospectus

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

424B3 | Prospectus

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)